Resilience is no longer a corporate slogan — it’s the new currency of survival in biopharma. As the sector races between scientific breakthroug...
Group sales revenue up 7.5 percent in the first nine months Significant growth in recurring business with consumables continues Bioproce...
The biopharmaceutical industry enters 2025 on strong footing, bolstered by scientific breakthroughs and a wave of digital innovation. In the post-AI market...
The €190 million acquisition of VISUfarma marks a pivotal moment in Lupin’s transformation into a global specialty-led biopharma. With VISUfarma...
In conversation with BioPharma BoardRoom, Amanda Haupt, Business Unit Manager for Base Editing at Revvity, shares insights into how the com...
23andMe Research Institute, Troper Wojcicki Philanthropies (TWP), and Lifebit today announced the official launch of an open-source data platform for the...
New Jersey at a Glance – Often dubbed the “Medicine Chest of the World,” New Jersey has a rich legacy and a dynamic present as a global h...
In this BioPharma Boardroom discussion, we speak with Christophe Hotermans, Head of Global Medical Affairs at Alexion, AstraZeneca Rare Disease. From the e...
Every aspect of science and research is based on data, and across the globe, labs are producing more data than the average person can even comprehe...
Since 2019, Cytiva has committed over $1.6 billion to expand its global manufacturing capacity. In this exclusive conversation with BioPharma BoardRoom, Pi...
ADCs are no longer a niche modality. To date, there are over a dozen approved ADCs on the market, and more than 500 programs are in clinical development, d...
In this exclusive interview with BioPharma BoardRoom, Jessay Devassy, Manager, Bioprocess Applications at Ecolab Bioprocessing&...
Novo Nordisk’s announcement of an executive reshuffle marks more than a routine leadership transition. It signals a strat...
10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31...
© 2025 Biopharma Boardroom. All Rights Reserved.
